Well Wikipedia says:
Commercialization
Neuren's analyst through Bell Porter reported that the company's estimated earnings before interest, taxation, depreciation, and amortization will be 84$ million at the end of 2016. This amount is expected to decrease by the end of 2017 to $27 million.[10] The promising results include estimates from upcoming licensing deals for Trofinetide and payment milestones from those deals. The product is expected to be available for commercial sale in 2019 for Rett Syndrome and in 2020 for Fragile X Syndrome.[10]
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.50 |
Change
-0.040(0.32%) |
Mkt cap ! $1.563B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.34 | $1.957M | 156.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 181 | $12.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.51 | 364 | 5 |
View Market Depth
| Last trade - 11.13am 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |